By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#66 – Vamsi Mootha, MD: Aging, T2D, cancer, dementia, Parkinson’s—do all roads lead to mitochondria?
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
CHAPTERS
- 0:04 – 20:14
The Broad Institute and Vamsi's path from math to medicine
Vamsi Mootha describes the Broad Institute's collaborative, genomics-driven model and his own path from math and computer science at Stanford through HST medical school and residency. He and Peter Attia discuss whether an MD and residency are worthwhile for aspiring researchers, and why he stopped seeing patients.
- •The Broad is a joint Harvard/MIT entity built around genomics, computation and collaboration, with a research scientist track
- •Mootha studied math and computer science, then did DNA sequence analysis before medical school
- •He applied to both research and clinical tracks at each stage, and credits medical school with teaching physiology
- •He stopped seeing patients five to six years ago to focus on developing diagnostics and drugs for mitochondrial disease
- 20:14 – 23:40
How a snowy night sparked a career in mitochondria
Mootha explains how a brief lecture on mitochondrial myopathies in his first semester of medical school, and then a textbook found at a relative's home during a snowstorm, hooked him on the organelle for good.
- •A single slide on mtDNA-related myopathies first caught his attention
- •He learned mitochondria were once bacteria with their own genomes
- •A textbook on a bookshelf in Somerville led him to devour the subject
- •Attia notes that most scientists don't have such a single eureka moment
- 23:40 – 32:42
Endosymbiosis, reductive evolution and the mitochondrial genome
Mootha walks through the endosymbiotic origin of mitochondria, a single event about 1.5 billion years ago, and how the organelle's genome shrank to 13 proteins. They cover the roughly 1,100 nuclear-encoded mitochondrial proteins and the disease mutations in mtDNA and nuclear genes.
- •Endosymbiosis of the mitochondrion appears to have happened only once, unlike the chloroplast
- •Reductive evolution left humans with a roughly 16,000-base genome encoding 13 proteins, two rRNAs and 22 tRNAs
- •About 1,100 nuclear-encoded proteins work with those 13
- •About 250 mtDNA syndromes and about 300 nuclear genes are linked to mitochondrial disorders
- 32:42 – 44:14
Mitochondrial biogenesis, AMPK, turnover and maternal inheritance
The conversation covers how exercise triggers mitochondrial biogenesis through AMPK, PGC-1alpha, calcium and NAD, and how mitochondria turn over within days. They then discuss why mtDNA is passed maternally and the recent reports of rare paternal transmission.
- •AMPK sensing of the ATP/ADP ratio is one input to a transcriptional program for biogenesis, though not sufficient alone
- •Androgens, calcium and NAD via SIRT1 also influence mitochondrial amount
- •The unfertilized egg has about half a million mtDNA copies; red blood cells have none
- •Mitochondria in non-dividing tissue have a half-life of a few days
- •Maternal inheritance results from dilution plus ubiquitin-tagged destruction of sperm mitochondria, with rare reported exceptions
- 44:14 – 56:09
Mitochondria 101: batteries, electron transport and NAD
Mootha and Attia explain mitochondria as energy transformers that convert food into electrical, proton and phosphorylation potentials. They cover NAD's role as an electron carrier and as a substrate for sirtuins and PARPs, and the decline of NAD and mitochondrial activity with age.
- •Mitochondria break down fuels and harness electrons, creating a voltage of about 150 millivolts across the inner membrane
- •That gradient drives ATP synthesis via oxidative phosphorylation
- •NAD works as a redox carrier and also as a substrate for sirtuins and PARPs
- •NAD content, mitochondrial amount and VO2 max decline with age; whether this is cause or consequence is unresolved
- 56:09 – 1:02:18
Rare mitochondrial diseases as a window into aging
Mootha describes the monogenic mitochondrial disorders his lab studies, such as Leigh syndrome, and why they provide cause-and-effect clarity. He frames them as hundreds of broken 'cars' that may inform the common wear-and-tear of aging.
- •About 300 inborn errors of mitochondrial metabolism are single-gene disorders where the defect is known at birth
- •Leigh syndrome, with about 80 causal genes, involves rapid neurodegeneration after a stressor in infancy
- •Mutations in neighboring subunits of the same complex can cause brain versus muscle disease for unknown reasons
- •Only a subset of these diseases may be relevant to common aging
- 1:02:18 – 1:22:08
Excess unused oxygen as a mechanism of mitochondrial disease
Mootha explains his lab's finding that broken mitochondria leave oxygen unused, and that this excess dioxygen may itself contribute to pathology rather than just ATP failure. They discuss how oxygen reaches mitochondria, venous oxygen and lactate in mitochondrial myopathy, and the link to early type 2 diabetes.
- •Mitochondria consume most of the oxygen we breathe and act as an oxygen sink
- •The lab's hypothesis is direct dioxygen toxicity to enzymes, not mainly reactive oxygen species
- •Patients with mitochondrial myopathy can show high cardiac output, low extraction, high venous oxygen and high lactate
- •Papers from 2003–2004 showed reduced mitochondrial gene expression in pre-diabetic muscle
- •Whether this is causal for diabetes remains unanswered, and Mendelian randomization is just becoming feasible
- 1:22:08 – 1:28:15
Mitochondrial decline, inflammation and the causality question
Attia raises the STING work linking mitochondrial DNA release to muscle inflammation, and Mootha explains why bacterial-like mitochondrial components such as DNA and formylated peptides are immunogenic. They then discuss whether mitochondrial decline drives aging and how to test it.
- •Mitochondrial DNA and formylmethionine peptides can trigger inflammatory pathways if released
- •A study of sterile crush injury identified mitochondrial-derived molecules as inflammatory triggers
- •No drug yet exists to rejuvenate mitochondria to test causality in aging
- •Exercise is one of the best ways to turn over bad mitochondria and induce good ones, but it does many things
- 1:28:15 – 1:40:50
Exercise, mitochondria, hysteresis and antioxidants
Attia shares his framework for exercise types and his interest in optimizing it for longevity. Mootha adds that mitochondria are lost quickly with disuse, that the exercise program involves many coordinated inputs, and that antioxidants can blunt exercise's benefits.
- •Attia divides exercise into strength, aerobic and anaerobic work and wants to know how to optimize limited weekly hours
- •VO2 max measurably falls after ten days of bed rest and takes about six weeks to recover
- •The PGC-1alpha program turns on biogenesis and autophagy together, cleansing bad mitochondria
- •A human study of exercise with or without antioxidants found antioxidants erased some benefits, suggesting ROS signaling matters
- 1:40:50 – 1:52:55
Metformin, complex I and Attia's lactate experiments
Attia describes his self-experiments showing higher lactate with metformin during exercise testing, and Mootha offers a metabolomics collaboration. Mootha suggests metformin may work through a homeostatic response to complex I inhibition, drawing on worm longevity screens, and agrees it could help some people and harm others.
- •Attia reports resting lactate of about 1–2 mM on metformin versus below 1 mM before, in an N of one
- •Mootha proposes metabolomics to compare on and off metformin
- •He thinks metformin works through the body's adaptive response to complex I inhibition
- •Worm RNAi screens show mild ETC disruption extends life while strong disruption shortens it
- •Attia asks whether metformin could blunt exercise adaptations, an open question
- 1:52:55 – 2:04:33
Hypoxia as a preclinical therapy for mitochondrial disease
Mootha explains his lab's finding that diluting oxygen to about 11 percent dramatically extends life in a mouse model of Leigh syndrome, while higher oxygen is fatal. He stresses that this is preclinical only and discusses hyperbaric oxygen and potential cancer applications.
- •Leigh syndrome mice normally die by about day 55 but survive to a median of about one year at 11% oxygen
- •Mice exposed to 55% oxygen die within a few days
- •Anecdotal reports followed of patients harmed by hyperbaric chambers
- •Flooding certain mitochondrially mutated tumors with oxygen is being explored, opposite to starving them
- •Mitochondrial folate-pathway enzymes are consistently upregulated across cancers
- 2:04:33 – 2:09:29
Parkinson's and the mitochondrial role across chronic diseases
Attia observes that cancer, Alzheimer's, atherosclerosis and diabetes all show mitochondrial signatures. Mootha singles out Parkinson's as the case where the causal hypothesis is most compelling, citing complex I deficiency in patients and toxins like rotenone.
- •Aged and diseased tissues show dysfunctional mitochondria, but cause versus effect is unclear
- •Monogenic mitochondrial disorders occur in about 1 in 4,000 while common diseases span a continuum
- •Parkinson's postmortem tissue shows complex I deficiency and increased mtDNA mutation burden
- •Complex I toxins such as certain pesticides and rotenone produce Parkinson-like disease
- 2:09:29 – 2:20:25
Optimism, protein prostheses and multi-pronged drugs
Despite Attia's pessimism, Mootha explains his optimism based on new tools such as hypoxia and protein prostheses taken from other organisms. They discuss why single-target drugs like metformin and statins work through broader homeostatic responses, and why natural products may be so potent.
- •Protein prostheses from other kingdoms of life can rescue human cells with ETC poisoning ex vivo
- •They partially correct redox imbalance but not proton pumping, so could be additive for diabetes or fatty liver
- •Engineering better mitochondria would require changing many parts, like turbocharging an engine
- •Statins hit HMG-CoA reductase but trigger a wider SREBP program including LDL receptor upregulation
- •Natural products have evolved over long arms races to target physiological systems
- 2:20:25 – 2:27:53
The dream experiment: thin air and the Indian Army data
Asked about a resource-unconstrained experiment, Mootha proposes housing thousands of people at 16,000 feet versus the plains to see whether chronic disease biomarkers improve. He cites an early-1970s Indian Army report of reduced diabetes, stroke and cardiovascular disease among troops at high altitude.
- •The proposed crossover study would compare luxury accommodations at altitude and on the plains for many months
- •Rodent experiments in more common disease models are ongoing in his lab
- •The Indian Army paper showed higher acute infection deaths at altitude but lower chronic disease incidence
- •Benefits were observed only while at altitude, with no long-term follow-up
